Trial Profile
A trial to examine the response and outcomes of enzalutamide-treated metastatic castration-resistant prostate cancer patients in the real-world context of prior treatments of abiraterone and/or docetaxel
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 17 May 2016 New trial record